Novo Nordisk (NOVOB DC) is seeking to widen access to obesity treatments in Japan by targeting patients willing to pay out of pocket for GLP-1 drugs such as Wegovy, Bloomberg reports
- The company will work with physicians and patients on self-funded treatment pathways, its Japan head Keisuke Kotani said.
Context
Novo Nordisk's initiative to expand access to obesity treatments in Japan represents a strategic move to tap into a lucrative market segment willing to pay out of pocket for GLP-1 drugs like Wegovy. This could enhance their revenue streams and market presence in a country with increasing obesity rates. Moreover, collaborating with healthcare providers could foster stronger relationships and potentially set a precedent for similar strategies across other regions.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#EUROPEAN EQUITIES